Comparison of microbial adherence to antiseptic and antibiotic central venous catheters using a novel agar subcutaneous infection model.
An agar subcutaneous infection model (agar model), which simulates the rat subcutaneous infection model (rat model), was developed to assess the ability of antimicrobial catheters to resist microbial colonization. The catheters were implanted in the agar and rat models and the insertion sites were infected immediately or on day 7, 14 or 21 post-implantation. The catheters implanted in the agar model were transferred to fresh media one day before infection on day 7, 14 or 21. The efficacy of chlorhexidine and silver sulfadiazine impregnated (CS) catheters, CS catheters with higher levels of chlorhexidine (CS+ catheters), minocycline-rifampicin (MR) catheters and silver catheters against Staphylococcus aureus and rifampicin-resistant Staphylococcus epidermidis RIF-r2 was compared in the agar and rat models. No significant difference in the adherence or the drug release was found between the in vitro and in vivo models. In both models, CS+ and MR catheters were effective against S. aureus even when infected on day 14, whereas CS catheters were colonized when challenged on day 7. CS+ catheters were effective against S. epidermidis RIF-r2, whereas MR catheters showed adherence when infected on day 7. CS+ catheters prevented colonization of all the organisms including, Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Candida albicans in the agar model, whereas MR catheters were effective only against S. aureus and S. epidermidis strains. Silver catheters were ineffective against all the organisms. The agar model may be used to predict the in vivo efficacy of antimicrobial catheters against various pathogens.
Gaonkar
Trupti A
TA
College of Physicians and Surgeons, Department of Surgery, 630 West 168th Street, New York, NY 10032, USA.
Modak
Shanta M
SM
D000362:Agar; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000891:Anti-Infective Agents, Local / Q000494:pharmacology*; D001422:Bacterial Adhesion / Q000187:drug effects*; D001424:Bacterial Infections / Q000382:microbiology; D002404:Catheterization; D002405:Catheterization, Central Venous / Q000295:instrumentation*; D002710:Chlorhexidine / Q000494:pharmacology; D003470:Culture Media; D004202:Disinfectants / Q000494:pharmacology; D005260:Female; D051381:Rats; D017207:Rats, Sprague-Dawley; D012837:Silver Sulfadiazine / Q000494:pharmacology; D012874:Skin Diseases, Infectious / Q000382:microbiology*
D000900:Anti-Bacterial Agents; D000891:Anti-Infective Agents, Local; D003470:Culture Media; D004202:Disinfectants; D000362:Agar; D002710:Chlorhexidine; D012837:Silver Sulfadiazine